Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-04-18 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
长城证券股份有限公司关于浙江泰林生物技术股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (长城证券股份有限公司) regarding the use of idle raised funds and own funds by 浙江泰林生物技术股份有限公司 for cash management. It includes background on fundraising, approval procedures, investment scope, risk control, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal audit or verification opinion related to the use of funds, which fits the category of an Audit Report / Information (AR). The document length is 3395 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2022
2022-04-18 Chinese
上海锦天城（杭州）律师事务所关于浙江泰林生物技术股份有限公司2022年限制性股票激励计划的法律意见书
Remuneration Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of Zhejiang Tailin Biotechnology Co., Ltd. It extensively discusses the legal compliance, procedures, and details of the stock incentive plan, including the plan's purpose, scope, stock allocation, legal basis, and procedural compliance. It is not a financial report, earnings release, or regulatory announcement but a legal opinion related to a stock incentive plan. This type of document is best classified under Remuneration Information (DEF 14A), as it details compensation-related stock incentive plans for executives and employees, consistent with the definition of Remuneration Information filings.
2022-04-18 Chinese
2022年限制性股票激励计划激励对象名单
Capital/Financing Update Classification · 95% confidence The document is titled as a list of incentive recipients under a 2022 restricted stock incentive plan by Zhejiang Tailin Biotechnology Co., Ltd. It details the allocation of restricted stock to various management and core personnel, including specific numbers of shares and percentages relative to the total plan and company stock. The document is a formal announcement from the company's board dated April 18, 2022. It does not contain financial statements, earnings data, or regulatory certifications. Instead, it focuses on the allocation of stock incentives to employees and management, which is a capital-related update about share-based compensation. This fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital structure through stock incentives.
2022-04-18 Chinese
独立董事2021年度述职报告（杨忠智）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2021 Annual Work Report" for Zhejiang Tailin Biotechnology Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on board matters, onsite inspections, committee work, investor protection efforts, and plans for 2022. The content is a detailed report of the independent director's activities and governance role during the year 2021. It is not an announcement or a brief summary but a substantive report on governance and board-related activities. This fits the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management. The document is not an annual report, audit report, or regulatory filing, but a specific governance-related report by an independent director.
2022-04-18 Chinese
独立董事2021年度述职报告（董明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2021 Annual Work Report" for Zhejiang Tailin Biotechnology Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on board matters, supervision of company governance and information disclosure, and plans for 2022. The content focuses on governance activities and oversight rather than financial results or audit opinions. It is a report by an independent director summarizing their duties and activities over the year, which aligns with Board/Management Information filings. The document length is 1846 characters, which is relatively short but contains substantive content about board activities and governance, not just an announcement or certification. Therefore, it is best classified as Board/Management Information (MANG).
2022-04-18 Chinese
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2021年度监事会工作报告" which translates to "2021 Supervisory Board Work Report". It details the supervisory board's activities, oversight of financial conditions, compliance with laws and regulations, internal control evaluations, and supervision of fundraising usage during the 2021 fiscal year. It includes detailed descriptions of meetings, agenda items, and supervisory opinions on the company's operations and financial reporting. The document is a comprehensive report on the supervisory board's work for the year 2021, which is a type of management or oversight report rather than a full annual report or audit report. It is not an announcement or a brief summary but a substantive report on governance and supervisory activities. Given the content and focus on supervisory board work and oversight, the most appropriate classification is "Management Reports (MDA)" which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports. The document length (4687 characters) supports it being a full report rather than a brief announcement or certification.
2022-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.